Sionna Therapeutics (SION) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Entrada Therapeutics (TRDA) has outperformed Sionna Therapeutics (SION) over the past year, losing 4.1% versus a loss of 83.2%. Entrada Therapeutics is the larger company by market cap ($218.4 million vs $217.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SION | TRDA |
|---|---|---|
| Share price | $4.82 | $5.61 |
| Market cap | $217.62M | $218.43M |
| 1-day change | +1.47% | +3.51% |
| YTD return | -88.28% | -45.43% |
| 1-year return | -83.15% | -4.10% |
| EPS (TTM) | $-2.16 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $54.97 | $16.45 |
| 52-week low | $4.01 | $5.15 |
| Distance from 52-week high | -91.23% | -65.90% |
| Analyst consensus | hold | none |
| Avg. price target upside | +335.68% | +238.68% |
| Average volume | 2.18M | 362.82K |
| Shares outstanding | 45.15M | 38.94M |
| Employees | 59 | 152 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRDA has outperformed SION by 79.1 percentage points over the past year.
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Healthcare · Biotechnology · 59 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Healthcare · Biotechnology · 152 employees
SION vs TRDA FAQ
Which is bigger, Sionna Therapeutics or Entrada Therapeutics?
Entrada Therapeutics (TRDA) is larger, with a market capitalization of $218.43M compared with $217.62M for Sionna Therapeutics (SION).
Which stock has performed better over the past year, SION or TRDA?
TRDA returned -4.10% over the past 12 months, compared with -83.15% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Sionna Therapeutics and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.